Vasomune Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.vasomune.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Phase 2
Recruiting
- Conditions
- Acute Respiratory Distress SyndromeViral or Bacterial InfectionsPneumoniaCOVID-19 Acute Respiratory Distress SyndromePneumonia, ViralRespiratory Infection
- Interventions
- Drug: AV-001 InjectionDrug: AV-001 Placebo Injection
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Vasomune Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05123755
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Denver Health Medical Center, Denver, Colorado, United States
🇺🇸University of Florida College of Medicine, Jacksonville, Jacksonville, Florida, United States
A First-in-Human Study of AV-001 in Healthy Subjects
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Vasomune Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT04737486
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
News
No news found